Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PROCEPT BioRobotics Corporation filings document the public-company disclosures of a Nasdaq-listed surgical robotics business focused on urology. Recent Form 8-K reports furnish quarterly financial results, revenue and operating commentary, investor presentation materials, and updates tied to the company’s AQUABEAM and HYDROS Robotic Systems, Aquablation therapy, and related product and clinical programs.
Proxy and governance filings cover board composition, committee assignments, director independence, executive compensation, equity awards, and severance or change-of-control arrangements. The filings also identify PRCT common stock registered under Section 12(b) and traded on The Nasdaq Global Market.
PROCEPT BioRobotics Corp director-linked entity Kestrel Fund, L.P. reported open-market purchases of 426,262 shares of common stock over several days. The buys occurred on March 5, 6 and 9, 2026 at weighted average prices generally between the low $20s and mid $20s per share, as detailed in price ranges in the footnotes. The filing also shows 35,152 shares held directly and 14,363 shares held indirectly by The 2:22 DNA Trust as of March 5, 2026. Antal Rohit Desai, a director and managing partner of CPMG, Inc., may be deemed to share voting and investment power over Kestrel Fund holdings but disclaims beneficial ownership except to the extent of any pecuniary interest.
PROCEPT BioRobotics President and CEO Larry L. Wood received equity awards on March 5, 2026. He was granted 103,653 stock options at an exercise price of $0.00 per share and 127,783 restricted stock units (RSUs) of common stock.
The RSUs vest over four years, with one-quarter vesting on March 5, 2027 and the remainder vesting quarterly over 36 months, conditioned on continued service. The stock options vest monthly over four years from March 5, 2026, also subject to continued employment or service.
PROCEPT BioRobotics EVP, CLO and Corporate Secretary Nouri Alaleh reported mixed equity transactions. On March 6, 2026, Alaleh sold 6,892 shares of Common Stock at an average price of $23.7019, with the shares sold to cover tax withholding obligations tied to vesting of restricted and performance stock units. Following this sale, direct ownership of Common Stock was 114,264 shares.
On March 5, 2026, Alaleh received 43,811 shares of Common Stock as a grant, structured as restricted stock units that vest over four years, beginning with one-quarter on March 5, 2027, and the remainder in quarterly installments. Alaleh was also granted a stock option for 29,615 shares, vesting in equal monthly installments over four years starting March 5, 2026, contingent on continued service.
PROCEPT BioRobotics EVP & CFO Kevin Waters reported a mix of equity awards and a tax-related share sale. On March 5, he received 47,462 restricted stock units and a stock option for 32,576 shares, both at no cash cost, with multi‑year vesting starting in March 2026–2027.
On March 6, he sold 6,721 shares of common stock at an average price of $23.7019 per share to cover tax withholding obligations tied to vesting RSUs and performance stock units. After the sale, he directly held 152,264 shares of common stock.
PROCEPT BioRobotics Corp director Dan Puckett received new equity awards. On March 5, 2026, he was granted stock options for 8,897 shares at an exercise price of $0.00 per share and 5,476 shares of common stock in the form of restricted stock units.
One-third of the stock options and one-third of the RSUs are scheduled to vest on March 5, 2027, with the remaining two-thirds of each award vesting in equal annual installments over the following two years, subject to his continued service with the company.
PROCEPT BioRobotics Corp director Dan Puckett filed an initial ownership report on Form 3. The filing lists him as a director of the company and does not report any share purchases, sales, acquisitions, or dispositions at this time.
Procept Biorobotics Corp ownership update: FMR LLC (with Abigail P. Johnson listed) reports beneficial ownership of 1,610,138.49 shares, representing 2.9% of Procept Biorobotics common stock on Schedule 13G/A (Amendment No. 5).
The filing lists sole dispositive power for FMR LLC of 1,610,138.49 shares and states that no other single person holds more than 5% of the class. Signature blocks show authorization via power of attorney.